Just In
- 1 hr ago Aditi Rao Hydari's Double Diamond Engagement Ring Is Unique, Celebrity Wedding Rings That Are Bookmark Worthy!
- 4 hrs ago Navratri 2024 Date In April: When Will Chaitra Navratri Festival Start? Significance Of 9 Days, Deets Inside!
- 5 hrs ago Ramadan 2024: 6 Bollywood-Inspired Outfit Ideas To Shine During The Holy Month
- 7 hrs ago Personality Traits Of April Born Babies: From Being Witty, To Charismatic And More, They Are Full Of Sheer Joy
Don't Miss
- Movies MasterChef Tamil, Telugu OTT Release Date, Platform, Contestants Name- All You Need To Know
- Automobiles Citroen Basalt Vs Tata Curvv – The Beauty Contest
- Finance 1:5 Stock Split, 10K Cr Fundraise Plan: Buy Multibagger PSU Bank Stock, TP Rs 140: Sharekhan
- Sports RCB vs KKR IPL 2024: Royal Challengers Bengaluru face Kolkata Knight Riders Match 10 Live Score & Updates From M Chinnaswamy Stadium: Match Starts at 7:30 PM
- News IndiGo Launches Daily Direct Flights Between Bengaluru And Bali
- Travel Choosing Your Next Home: Hyderabad Or Pune?
- Education National Management College begins admissions for CA and CMA courses
- Technology Samsung Galaxy M15 5G Launch in India Teased; Could Be Priced Under Rs 15,000
UK Scientists Trial First Needle-Free Air-Powered COVID-19 Vaccine
Scientists at the University of Cambridge on Tuesday began a clinical trial of a needle-free air-powered vaccine, which is expected to help combat future variants of COVID-19.
Developed by Professor Jonathan Heeney at the University of Cambridge and spin-out company DIOSynVax, the new DIOSvax technology is dubbed a next-generation coronavirus vaccine administered through a blast of air that delivers the dose into the skin.
It offers a possible future alternative to people who fear needle-based jabs and, if successful, it could be scaled up and manufactured as a powder to boost global vaccination efforts, particularly in low and middle-income countries.
"The response of the scientific and medical communities to the development and delivery of COVID-19 vaccines has been incredible, but as new variants emerge and immunity begins to wane we need newer technologies," said Heeney.
"It's vital that we continue to develop new generation vaccine candidates ready to help keep us safe from the next virus threats. Our vaccine is innovative, both in terms of the way it primes the immune system to respond with a broader protective response to coronaviruses, and how it is delivered. Crucially, it is the first step towards a universal coronavirus vaccine we are developing, protecting us not just from COVID-19 variants but from future coronaviruses," he said.
The first volunteer will receive the vaccine this week at the NIHR Southampton Clinical Research Facility.
The COVID-19 SARS-CoV-2 virus uses "spike" proteins on its surface to gain entry to host cells. These proteins bind to ACE2, a protein receptor on the surface of cells in our airways, allowing the virus to release its genetic material into the host cell. The virus hijacks the host cell's machinery to allow itself to replicate and spread.
Vaccines inform our bodies about what dangerous infections look like and how to respond to them. This is much safer than becoming infected with the live virus, because it avoids the life-threatening effects the whole virus can have.
Immunisation arms our immune system to look out for and block viruses, or destroy cells that carry the spike protein, protecting us from COVID-19 disease. Unfortunately, SARS-CoV-2 is constantly mutating and the virus spike protein itself is changing. This raises the prospect of "vaccine escape", where changes to the spike protein mean the immune system is no longer able to recognise it.
To get around this problem, the Cambridge University team searched for new types of antigens - key regions of the virus - that are the same across coronaviruses that occur in nature, including in animals that carry them, such as bats.
While most COVID-19 vaccines use the sequence of the RNA for the virus spike protein from the first isolated samples of the COVID-19 virus in January 2020, the new DIOSvax technology uses predictive methods to encode antigens like the spike protein that mimic the wider family of coronavirus antigens, thus giving wider protection.
Professor Heeney explained: "DIOS-CoVax vaccines target elements of the virus structure that are common to all known 'beta-coronaviruses' - those coronaviruses that are the greatest disease threats to humans. These are structures that are vitally important to the virus life cycle, which means we can be confident that they are unlikely to change in the future.
"These next-generation DIOSvax vaccines should protect us against variants we've seen so far - alpha, beta, delta variants, for example - and hopefully future-proof us against emerging variants and potential coronavirus pandemics."
Funding for the needle-free vaccine and trial was provided by Innovate UK, part of the UK Research and Innovation network.
- wellnessGap Between Second And Precaution Dose Of Covid-19 Vaccine Reduced To 6 Months
- wellnessNovel Inhalable Covid-19 Vaccine Is Stable At Room Temperature: Study
- wellnessNTAGI To Review Covaxin Corbevax Data For 6-12 Years Thursday, Discuss Reducing Booster Dose Gap
- wellnessEven Vaccinated People Can Develop Long Covid, Study Finds
- wellnessBooster Dose Of COVID Vaccine Needed To Fight Against Omicron: Study
- basicsNovavax's Covid-19 Vaccine Covovax Gets Emergency Use Authorisation For 12-17 Age Group In India
- wellnessAIIMS Delhi To Start Booster Dose Trial Of Intranasal Covid Vaccine From March 11
- wellnessDecision On COVID-19 Vaccine Precaution Dose For All Adults Will Be Based On Scientific Need: Govt
- healthIsrael To Administer Fourth Dose Of COVID-19 Vaccine For Medical Personnel And Senior Citizens
- healthHospital Launches Vaccination Programme For Children Aged 15-18 Yrs Across The Country
- healthSII Gets DCGI Nod To Manufacture Drug Substance, Test It For Developing Jab Against Omicron
- healthDecision On Which Vaccine To Be Given As Precautionary Dose Expected Soon: Govt